Payment overview · 2025
General Payments
$534.68
5 reported records · 5 companies
Healthcare provider profile · identity verified
Sunpreet Kaur Ranu, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FRESNO, CA · NPI 1205418480
Verified facts
What the public records show
CMS Open Payments records show Sunpreet Kaur Ranu, NP received $534.68 in general payments during 2025 across 5 reported records.
Amgen Inc. accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $148.15 | 27.7% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $127.48 | 23.8% | 1 | 2025 |
| Amarin Pharma, Inc. | Unresolved — no canonical attribution shown | $96.19 | 18.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.97 | 15.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $79.89 | 14.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $534.68 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $148.15 | 1 | 2025 |
Source payment records
|
|||||
| Vascepa Normalized: vascepa |
Drug | Amarin Pharma, Inc. | $96.19 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $82.97 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $79.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 506 | 79 |
| Alendronate Sodium | Alendronate Sodium | 319 | 50 |
| Gabapentin | Gabapentin | 316 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 41 |
| Metformin Hcl | Metformin Hcl | 203 | 30 |
| Losartan Potassium | Losartan Potassium | 200 | 33 |
| Lisinopril | Lisinopril | 194 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 18 |
| Furosemide | Furosemide | 122 | 28 |
| Omeprazole | Omeprazole | 120 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 119 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 14 |
| Sertraline Hcl | Sertraline Hcl | 97 | 12 |
| Carvedilol | Carvedilol | 88 | 15 |
| Eliquis | Apixaban | 79 | 14 |
| Donepezil Hcl | Donepezil Hcl | 73 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | suppressed |
| Latanoprost | Latanoprost | 65 | suppressed |
| Simvastatin | Simvastatin | 59 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 58 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 51 | suppressed |
| Olanzapine | Olanzapine | 50 | suppressed |
| Famotidine | Famotidine | 47 | suppressed |
| Atenolol | Atenolol | 45 | suppressed |
| Jardiance | Empagliflozin | 45 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 44 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 39 | suppressed |
| Telmisartan | Telmisartan | 38 | suppressed |
| Lactulose | Lactulose | 36 | 12 |
| Meloxicam | Meloxicam | 36 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Tradjenta | Linagliptin | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 34 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 18 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 15 |
| Ibuprofen | Ibuprofen | 29 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Mirabegron Er | Mirabegron | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Azithromycin | Azithromycin | 18 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 11 |
| Metformin Er Osmotic | Metformin Hcl | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Alogliptin | Alogliptin Benzoate | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $534.68 · 5 records | Amgen Inc. | KRYSTEXXA, Leqembi, Vascepa, ZAVZPRET | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error